Shattuck Labs (STTK) Non Operating Income (2019 - 2026)
Shattuck Labs (STTK) reported Non Operating Income of $778000.0 for Q1 2026, up 39000.0% year-over-year from N/an in Q1 2025, and little changed on a QoQ basis from $778000.0 in Q4 2025.
Shattuck Labs (STTK) has 8 years of Non Operating Income data on file, last reported at $778000.0 in Q1 2026.
- Quarterly Non Operating Income rose 39000.0% year-over-year to $778000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 278.96% YoY) and the FY2025 annual result came in at $2.7 million, up 15976.47% from the prior year.
- Non Operating Income steadied at $778000.0 in Q1 2026 per STTK's latest filing, from $778000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.5 million in Q1 2024 and bottomed at -$4.2 million in Q4 2024.
- The 5-year median for Non Operating Income is $778000.0 (2025), against an average of $243823.5.
- The widest annual swing landed in 2023, when Non Operating Income plunged 493.64%; it then surged 39000.0% in 2026.
- Tracing STTK's Non Operating Income over 5 years: stood at $865000.0 in 2022, then sank by 493.64% to -$3.4 million in 2023, then slipped by 23.7% to -$4.2 million in 2024, then surged by 118.47% to $778000.0 in 2025, then changed by 0.0% to $778000.0 in 2026.
- Per Business Quant, the three latest STTK Non Operating Income figures stand at $778000.0 (Q1 2026), $778000.0 (Q4 2025), and $660000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Shattuck Labs | 667.80 Mn | 667.80 Mn | - | 778,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 778,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Sep 30, 2025 | 660,000.00 |
| Jun 30, 2025 | 574,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | -4.21 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | -3.41 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 937,000.00 |
| Dec 31, 2022 | 865,000.00 |
| Sep 30, 2022 | 594,000.00 |
| Jun 30, 2022 | 287,000.00 |
| Mar 31, 2022 | -362,000.00 |
| Dec 31, 2021 | -2.02 Mn |
| Sep 30, 2021 | 170,000.00 |
| Jun 30, 2021 | 914,000.00 |
| Mar 31, 2021 | 610,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Jun 30, 2020 | -26,000.00 |
| Mar 31, 2020 | -43,000.00 |
| Dec 31, 2019 | 255,000.00 |
| Sep 30, 2019 | 248,000.00 |